BGC1201: A potent allosteric SHP2 inhibitor with broad antitumor activity in lung, pancreatic, and esophageal cancer xenografts.
BGC1201 is a potent allosteric SHP2 inhibitor showing significant antitumor activity in preclinical models, but its clinical application remains to be established.
Where it sits
this study against the rest of the ara 290 corpusSummary and findings
BGC1201 is a novel allosteric SHP2 inhibitor evaluated for its antitumor activity. It inhibited SHP2-WT phosphatase with an IC50 of 2.47 nM and showed antiproliferative activity against 12 of 14 tumor cell lines. In nude mouse xenograft models, it produced significant tumor growth inhibition with a dose-dependent trend.
Abstract
BGC1201 is a novel allosteric SHP2 inhibitor developed via fragment-based drug design (FBDD). It potently inhibited SHP2-WT phosphatase with an IC<sub>50</sub> of 2.47 nM and suppressed p-ERK expression in NCI-H358 cells with an IC<sub>50</sub> of 17.3 nM. BGC1201 showed weak inhibition of the hERG potassium channel, with an IC<sub>50</sub> value > 40 μM, suggesting a low hERG-related liability in vitro. In a panel of 14 tumor cell lines, BGC1201 showed antiproliferative activity against 12 lines, with IC<sub>50</sub> values ranging from 0.0236 to 8.66 μM, while sparing normal HUVEC cells. In nude mouse xenograft models of human lung (NCI-H358), pancreatic (MIA PaCa-2), and esophageal (KYSE-520) cancers, oral administration of BGC1201 produced significant tumor growth inhibition with a dose-dependent trend. Western blot analysis further confirmed that BGC1201 reduced p-ERK levels in tumor tissues in a time-dependent manner. Pharmacokinetic evaluation in rats showed that BGC1201 achieved measurable oral exposure and was eliminated through multiple metabolic and excretory pathways. These findings support BGC1201 as a promising candidate for further anticancer drug development.
Background
This study investigates BGC1201, a novel allosteric SHP2 inhibitor, which is important given the role of SHP2 in cancer progression. Prior knowledge indicated that SHP2 is a promising target for cancer therapy, but effective inhibitors were lacking. Understanding the efficacy of BGC1201 in various cancer types could inform future therapeutic strategies.
Methods
The study utilized fragment-based drug design to develop BGC1201, followed by in vitro assays to determine IC50 values for SHP2-WT phosphatase and p-ERK expression. Antiproliferative activity was assessed across 14 tumor cell lines, and in vivo efficacy was evaluated in nude mouse xenograft models of lung, pancreatic, and esophageal cancers. The pharmacokinetics of BGC1201 were also assessed in rats.
Results
BGC1201 inhibited SHP2-WT phosphatase with an IC50 of 2.47 nM. In tumor cell lines, it showed IC50 values ranging from 0.0236 to 8.66 μM for antiproliferative activity. In vivo, BGC1201 produced significant tumor growth inhibition in xenograft models, with a dose-dependent trend observed.
Interpretation
The findings suggest that BGC1201 is a potent inhibitor of SHP2, with significant effects in preclinical models. However, while the IC50 values indicate strong activity, the clinical relevance remains uncertain until human trials are conducted. The study's reliance on animal models and in vitro data introduces confounding factors that may limit the generalizability of the results.
Key findings
- IC50 of 2.47 nM for SHP2-WT phosphatase inhibition.
- IC50 of 17.3 nM for p-ERK expression suppression in NCI-H358 cells.
- IC50 values for antiproliferative activity ranged from 0.0236 to 8.66 μM across 12 tumor cell lines.
- BGC1201 showed weak inhibition of the hERG potassium channel with an IC50 value > 40 μM.
- Significant tumor growth inhibition observed in nude mouse xenograft models with a dose-dependent trend.
Limitations
- Primarily in vitro and animal model data.
- Small sample sizes in preclinical studies.
- No human data reported.
- Short duration of follow-up in animal studies.